|1.||Asnacios, Amani: 2 articles (06/2008 - 04/2007)|
|2.||Poynard, Thierry: 2 articles (06/2008 - 04/2007)|
|3.||Vardakis, Nikolaos: 2 articles (01/2008 - 12/2006)|
|4.||Papakotoulas, Pavlos: 2 articles (01/2008 - 12/2006)|
|5.||Vamvakas, Lambros: 2 articles (01/2008 - 12/2006)|
|6.||Kalykaki, Antonia: 2 articles (01/2008 - 12/2006)|
|7.||Georgoulias, Vassilis: 2 articles (01/2008 - 12/2006)|
|8.||Zhao, Zhe: 1 article (04/2015)|
|9.||Chen, Bi-Ling: 1 article (04/2015)|
|10.||Tan, Qing-Ling: 1 article (04/2015)|
|1.||Pancreatic Neoplasms (Pancreatic Cancer)
12/01/2007 - "This study was to analyze the efficacy of GEMOX regimen on advanced pancreatic cancer, and observe the adverse events. "
08/01/2007 - "Analyses of the available evidences suggest GEMOX regimen is promising as the first-line therapy for advanced pancreatic cancer, which encourages further clinical trials."
12/01/2007 - "But in China, the use of GEMOX regimen for advance pancreatic cancer has seldom been reported. "
08/01/2007 - "This meta-analysis included all randomized evidences to compare GEMOX regimen with GEM alone with respect to overall survival rate and adverse events in patients with advanced pancreatic cancer. "
08/01/2007 - "This study was to evaluate the efficacy of GEM of fixed-dose rate infusion plus oxaliplatin (GEMOX regimen) as first-line therapy for advanced pancreatic cancer by meta-analysis. "
|2.||Ovarian Neoplasms (Ovarian Cancer)
01/01/2013 - "GEMOX regimen is very effective to treat advanced ovarian cancer, with low toxicity, good tolerance and improved life quality in patients."
01/01/2013 - "Phase II clinical study on the GEMOX regimen as second- line therapy for advanced ovarian cancer."
01/01/2008 - "The GEMOX regimen has moderate activity in both platinum-sensitive and resistant ovarian cancer and a toxicity profile that can be significant and therefore requires careful monitoring."
01/01/2008 - "The aim of this study was to evaluate the safety and activity of a gemcitabine-oxaliplatin combination (GEMOX) regimen in pretreated patients with advanced ovarian cancer. "
01/01/2013 - "To investigate the effectiveness and adverse effects of gemcitabine by fixed-dose rate infusion plus oxaliplatin (GEMOX regimen) as second-line therapy for advanced ovarian cancer. "
03/01/2010 - "Safety and efficacy of single-day GemOx regimen in patients with pancreatobiliary cancer: a single institution experience."
10/01/2010 - "By reviewing the literature we found that the Gemox regimen seems to be active in the treatment of various kinds of tumors and is well tolerated. "
01/01/2006 - "The interesting tumor growth control rate and the favorable toxicity profile of the GEMOX regimen in pretreated patients with advanced CRC strongly suggest that this regimen may provide an alternative therapeutic option for this group of patients."
12/01/2007 - "Clinical data of 32 chemonaive patients with stage III-IV pancreatic cancer, treated with GEMOX regimen [intravenous injection of gemcitabine (1 000 mg/m(2)) at Day 1 and Day 8, and intravenous injection of oxaliplatin (85-130 mg/m(2)) at Day 1; repeated every 21 days] at Cancer Center of Sun Yat-sen University from Feb. "
|4.||Thyroid Neoplasms (Thyroid Cancer)
|5.||Hepatocellular Carcinoma (Hepatoma)
|1.||Drug Therapy (Chemotherapy)